DexCom Overview
| Company: | DexCom |
|---|---|
| CEO: | Jereme Sylvain |
| Symbol: | DXCM |
| Exchange: | NASDAQ |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| About |
DexCom, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its productslude DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom wasorporated in 1999 and is headquartered in San Diego, California. |
-
Ranking:
65 among 2854 companies
-
Address:
6340 Sequence Drive
-
City | State | Country:
San Diego | CA |
US
- Phone:
-
Website:
-
Revenue
Net Income
Employees
Revenue by Segment
Revenue by Region
Executive Salary
Revenue per Employee
Profit per Employee
Income Statement
Operating Income
Research & Development
Tax Rate (%)
Assets & Liabilities | Cash Flow
Total Assets
Total Liabilities
Capital Expenditure
Ratios
Return on Equity (ROE)
Return on Assets (ROA)
Debt to Equity
Profitability
Gross Profit Margin (%)
Operating Income Margin (%)
Net Income Margin (%)
Earning Per Share
EBITDA
Free Cash Flow (FCF)
Valuation
Enterprise value
Enterprise value to Revenue
Enterprise value to EBITDA
Competitors’ Revenue
Frequently Asked Questions
